Skip to content

D&A at other companies

Eli Lilly logo
Eli LillyLLY
$509M+9.9%
Bausch Health Companies logo
Bausch Health CompaniesBHC
$295M-3.3%

Segments

By segment

See full
Reportable Segment$3.02M-6.8%

Other financials

Income statement

See full
Revenue$39.4M0.0%
Gross profit$23.8M+1.6%
Operating income-$1.8M-13.4%
Net income-$2.4M+15.8%
EPS (diluted)-$0.03+40.0%

Balance sheet

See full
Cash & equivalents$16.7M+201%
Total debt$71.0M-27.1%
Total equity$100.3M+31.5%
Total assets$192.0M-5.5%

Cash flow

See full
Operating cash flow$5.3M+507%
CapEx$51.0K-97.3%
Free cash flow$5.2M+605%

Valuation

See full
Market cap$311.81M+4.7%
Enterprise value$366.14M-6.0%
P/S2.1×+0.3×

Profitability

See full
Gross margin59.6%-0.3pp
Operating margin-7.8%-0.4pp
Net margin-11.3%-25.1pp
FCF margin-0.1%

Returns & leverage

See full
Return on equity-21.6%-78.3pp
Debt / equity0.7×-0.6×
Current ratio0.7×+0.2×

Where this comes from

Reported directly by AirSculpt Technologies, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: AirSculpt Technologies, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AirSculpt Technologies, Inc.'s d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AirSculpt Technologies, Inc.'s D&A?
AirSculpt Technologies, Inc. (AIRS) reported D&A of $3.02M in Q1 2026.
How has AirSculpt Technologies, Inc.'s D&A changed year-over-year?
AirSculpt Technologies, Inc.'s D&A decreased by 6.8% year-over-year, from $3.24M to $3.02M.
What is the long-term trend for AirSculpt Technologies, Inc.'s D&A?
Over 4 years (2021 to 2025), AirSculpt Technologies, Inc.'s D&A has grown at a 18.0% compound annual growth rate (CAGR), from $6.6M to $12.78M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.